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Inhibition of the Prohormone Convertase
Subtilisin-Kexin Isoenzyme-1 Induces Apoptosis
in Human Melanoma Cells
Nina Wei 1, Agatha Stegemann1, Marwa A.T. Elsayed2, Karin U. Schallreuter2,3, Thomas A. Luger1,
Karin Loser1, Dieter Metze1, Carsten Weishaupt1 and Markus Bo¨hm1
Prohormone convertases (PCs) are endoproteases that process many substrates in addition to hormone
precursors. Although overexpression of PCs is linked to carcinogenesis in some solid tumors, the role of
subtilisin-kexin isoenzyme-1 (SKI-1) in this context is unknown. We show that SKI-1 is constitutively expressed in
human pigment cells with higher SKI activity in seven out of eight melanoma cell lines compared with normal
melanocytes. SKI-1 immunoreactivity is also detectable in tumor cells of melanoma metastases. Moreover, tissue
samples of the latter display higher SKI-1 mRNA levels and activity than normal skin. From various stimuli tested,
12-O-tetradecanoylphorbol-13-acetate and tunicamycin affected SKI-1 expression. Importantly, SKI-1 inhibition by
the cell-permeable enzyme inhibitor decanoyl-RRLL-chloromethylketone (dec-RRLL-CMK) not only suppressed
proliferation and metabolic activity of melanoma cells in vitro but also reduced tumor growth of melanoma cells
injected intracutaneously into immunodeficient mice. Mechanistic studies revealed that dec-RRLL-CMK induces
classical apoptosis of melanoma cells in vitro and affects expression of several SKI-1 target genes including
activating transcription factor 6 (ATF6). However, ATF6 gene silencing does not result in apoptosis of melanoma
cells, suggesting that dec-RRLL-CMK induces cell death in an ATF6-independent manner. Our findings encourage
further studies on SKI-1 as a potential target for melanoma therapy.
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INTRODUCTION
Prohormone convertases (PCs) are evolutionary conserved
serine proteases that were initially characterized as enzymes
processing precursor hormones such as proopiomelanocortin
or proenkephalin (Seidah and Chre´tien, 1999a; Seidah, 2011).
They include PC1/3, furin, PC4, PC5/6, paired basic amino
acid cleaving enzyme 4, PC7, subtilisin-kexin isoenzyme-1
(SKI-1), and PC subtilisin/kexin 9. The first seven of these
PCs cleave substrates within the motif (K/R)–(X)n–(K/R)k,
where n¼ 0, 2, 4, or 6 and X is any amino acid except
Cys. SKI-1 cleaves at the consensus motif (R/K)–X–
(hydrophobic)–X, where X is variable (Pasquato et al., 2006),
whereas PC subtilisin/kexin 9 cleaves behind VFAQk
(Benjannet et al., 2004).
SKI-1 belongs to the most recently discovered PCs (Seidah
et al., 1999b). It regulates cartilage development (Schlombs
et al., 2003), bone mineralization (Gorski et al., 2009), and
processing of viral glycoproteins, e.g., those of Lassa virus
(Lenz et al., 2001). SKI-1 activates the sterol regulatory
element binding proteins 1 and 2 (Espenshade et al., 1999);
hence, it is a key regulator of lipid metabolism. Accordingly,
pharmacological inhibitors are being developed for the
future treatment of dyslipidemia (Seidah and Prat, 2007).
The essential role for SKI-1 is highlighted by genetic ablation
studies. Here, global SKI-1 deficiency leads to early
embryonic death of mice (Yang et al., 2001).
In this study, we investigated the expression, regulation, and
function of SKI-1 in normal human melanocytes (NHMs) and
melanoma cells. Our study was inspired by increasing
numbers of reports that indicate a role for PCs, especially
furin and paired basic amino acid cleaving enzyme 4, in
tumor progression and metastasis of some solid tumors (Bassi
et al., 2005). In this context, it was shown that PC1/3, PC2,
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and furin are expressed in NHMs (Peters et al., 2000; Spencer
et al., 2008). However, little is known about PCs and their
potential role in malignant transformation of melanocytes,
respectively. Here, we show that SKI-1 is constitutively
expressed in pigment cells. Using a small-peptide SKI-1
inhibitor, we were able to pinpoint an essential role of this
enzyme in the growth and survival of melanoma cells. On the
basis of our observations, we suggest a biological role of SKI-1
in melanoma development. Moreover, our data support SKI-1
as a potential target for melanoma treatment.
RESULTS
Detection of SKI expression and activity in human pigment cells
in vitro
We first examined the expression of SKI-1 in NHMs and
human melanoma cell lines. The latter included WM35 (radial
growth phase) and WM902B (vertical growth phase of a
primary melanoma); IPC298, A375, G361 (advanced primary
melanomas); and SK-Mel-30, IGR37, and WM9 (metastases).
Real-time reverse transcriptase-PCR (RT-PCR) analysis
revealed similar mRNA levels of SKI-1 in NHMs and mela-
noma cells (Figure 1a). The identity of the amplification
product in one representative melanoma cell line (IPC298)
was confirmed by DNA sequencing and was found to be
identical to the mRNA sequence of SKI-1, as deposited in the
NCBI (data not shown). Western immunoblotting confirmed
these findings. Here, a single band ofB100 kDa was detected.
It comigrated with the positive control (HepG2), indicating
fully processed SKI-1 (Figure 1b). Notably, SKI-1 protein was
also detected in conditioned media of melanoma cells, as
shown by one representative melanoma cell line (Figure 1c).
Immunofluorescence analysis demonstrated that SKI-1 immu-
noreactivity is detectable in NHMs as a faint cytoplasmic
staining. A speckled immunostaining was also seen in nuclei of
NHMs, albeit this staining was more prominent in SK-Mel-30
melanoma cells. By contrast to PC1/3 and PC2 (Peters et al.,
2000), SKI-1 did not colocalize in NHMs with the
premelanosomal marker NKI/beteb (Figure 1d). In melanoma
cells, SKI-1 further colocalized with some melanosomes
(Figure 1e). Negative controls consisting of omission of the
first antibody (Ab) did not show any staining (data not shown).
To clarify whether the detected SKI-1 in pigment cells is
active, we established SKI-1 enzyme assays using the synthetic
fluorogenic substrate Ac-RSLK-AMC. Interestingly, SKI-1
activity in conditioned media (Figure 1f), but not in total cell
lysates (Supplementary Figure S1 online), was significantly
elevated in seven out of the eight melanoma cell lines
compared with NHMs.
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Figure 1. Subtilisin-kexin isoenzyme-1 (SKI-1) expression and activity in human pigment cells in vitro. Real-time reverse transcriptase-PCR of SKI-1 in
normal human melanocytes (NHMs) and melanoma cell lines; n¼3 (a). SKI-1 expression in cell lysates of NHMs and melanoma cell lines (15mg per lane),
as shown by western immunoblotting (b). Results are based on triplicate experiments. Detection of SKI-1 in conditioned media of melanoma cells as shown by
western immunoblotting (40mg per lane) (c). Subcellular localization of SKI-1 in NHMs (d) and SK-Mel-30 melanoma cells (e), as shown by immunofluorescence
analysis. Note cytoplasmic (asterisks) and nuclear SKI-1 immunostaining (arrows). Results are based on triplicate experiments. Bar¼30mm. SKI-1 activity
in conditioned media of NHMs and melanoma cell lines (f). Normalized conditioned media were incubated for 3 hours with Ac-RSLK-AMC. *Po0.05;
**Po0.01; ***Po0.001.
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Expression and activity of SKI-1 in normal human skin and
metastatic melanoma
Next, we investigated whether SKI-1 expression is altered in
human melanoma tissue samples compared with normal skin.
Real-time RT-PCR of RNA prepared from cryomaterial of
normal skin and melanoma metastases (each n¼5) disclosed
significantly increased mRNA levels of SKI-1 in melanoma
tissue (Figure 2a). SKI-1 immunofluorescence analysis of
healthy skin (n¼5) revealed a distinct cytoplasmic staining
confined to suprabasal epidermal keratinocytes (Figure 2b).
Notably, SKI-1 immunofluorescence was absent in the basal
epidermal layer. In situ double immunostaining of SKI-1 and
NKI/beteb confirmed the absence of SKI-1 in epidermal
melanocytes (Figure 2c). However, in accordance with our
ex vivo SKI-1 mRNA analysis, we detected SKI-1 immuno-
reactivity in tumor cells of melanoma metastases (n¼5;
Figure 2b and c). Negative controls consisting of replacement
of primary Ab with the isotype control confirmed the speci-
ficity of this staining (Figure 2b). Moreover, SKI-1 activity was
significantly elevated in homogenized tissue samples of
melanoma metastases compared with normal skin (each
n¼5; Figure 2d).
Regulation of SKI-1 expression in NHMs
To get a first insight into SKI-1 regulation in pigment cells,
we performed in silico promoter analysis. We focused on
transcription factor (TF)–binding sites that are activated in
NHMs by mitogens, proinflammatory signals, and endo-
plasmic reticulum stress. Consensus sequences in the
upstream promoter of SKI-1 were found for cAMP response
element binding protein (CREB) (-934; -1309), activator
protein (AP)-1 (-2984; -2983; -2723; -2156; -888), NF-kB
(-2756; -2383; -2381), and activating transcription factor 6
(ATF6) (-3024; -553) (Supplementary Figure S2a online).
Thus, we determined by RT-PCR the effects of established
CREB activators forskolin, a-melanocyte-stimulating hormone
(a-MSH), and basic fibroblast growth factor (Bo¨hm et al.,
1995; Suzuki et al., 1996; Tada et al., 2002), as well as
12-O-tetradecanoylphorbol-13-acetate (TPA) an activator of
protein kinase C and AP-1, on SKI-1 expression in NHMs.
Stimulation with forskolin (10mM), a-MSH (106 M), and basic
fibroblast growth factor (10 ng ml1) for 3–24 hours did not
affect SKI-1 expression (data not shown), whereas TPA
decreased SKI-1 levels when stimulated for 6–12 hours
(Supplementary Figure S2b online). Exposure of NHMs to
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Figure 2. Subtilisin-kexin isoenzyme-1 (SKI-1) expression and activity in normal human skin and melanoma metastases. SKI-1 mRNA levels in tissue samples
of normal human skin and melanoma metastases as shown by real-time reverse transcriptase-PCR (a), n¼ 5 each; #Po0.05. Immunofluorescence analysis
of SKI-1 in normal human skin and metastatic melanoma (b). One representative set of n¼5 each is shown. Bar¼ 30mm. D, dermis, E, epidermis. Double
immunostaining of SKI-1 and NKI/beteb in normal human skin and melanoma metastases (c). Bar¼ 30mm. Localization of antigens is highlighted by arrows.
One representative set n¼ 5 each is shown. SKI-1 activity in tissue samples of normal human skin and melanoma metastases (d). Tissue lysates (n¼ 5 each)
were normalized for protein and incubated for 3 hours with the SKI-1 substrate Ac-RSLK-AMC (#Po0.05). NKI, normal human melanocytes.
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UVB (10 mJ cm 2, 2–24 hours), IL-1b (1 ng ml1; 8 hours), or
tumor necrosis factor-a (10 ng ml1, 8 hours), all activators of
NF-kB signaling, failed to alter SKI-1 mRNA levels (data not
shown). In contrast, the endoplasmic reticulum stressor tuni-
camycin (Shen and Prywes, 2005) increased SKI-1 mRNA
expression after 6–12 hours (Supplementary Figure S2c
online).
SKI-1 inhibition suppresses the growth of melanoma cells
in vitro and in vivo
We wondered how SKI-1 inhibition affects human pigment
cells, especially melanoma cells. We used the selective and
cell-permeable small-peptide inhibitor decanoyl-RRLL-chloro-
methylketone (dec-RRLL-cmk; Pasquato et al., 2006) to this
end. First, we confirmed in one representative melanoma cell
line that dec-RRLL-cmk reduces SKI-1 activity in vitro.
Intracellular SKI-1 activity declined in a dose-dependent
manner after treatment of SK-Mel-30 cells with dec-RRLL-
cmk for 24 hours (Figure 3a). As early as 30 minutes after
dec-RRLL-cmk (50mM), SKI-1 activity declined and was signi-
ficantly suppressed after 6 hours to B10% of control cells
(Figure 3b). In accordance with this finding, dec-RRLL-cmk
also reduced the expression of glucose-regulated protein 78
(GRP78), which has previously been shown to be regulated by
ATF6 via SKI-1 activation (Ye et al., 2000). Accordingly,
tunicamycin induced GRP78 expression in SK-Mel-30 cells,
and this response was reduced dose dependently by dec-
RRLL-cmk (Figure 3c and d).
Next, we examined the in vitro effect of dec-RRLL-cmk on
proliferation of NHMs and four randomly chosen melanoma
cell lines by 2,3-Bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tet-
razolium-5-carboxanilid-salt and crystal violet assays. Dec-
RRLL-cmk had a dose-dependent inhibitory effect on meta-
bolic activity and cell survival of both NHMs and melanoma
cells (Supplementary Figure S3a and b online and Figure 4a
and b). The IC50 values of dec-RRLL-cmk, as measured by
crystal violet assay, were 45mM for NHMs, 33mM for SK-Mel-
30, 25mM for G361, 29mM for IPC298, and 34mM for WM9,
suggesting that melanoma cells under the given experimental
conditions are more sensitive than NHMs toward the SKI-1
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Figure 3. Decanoyl-RRLL-chloromethylketone (Dec-RRLL-cmk) suppresses
subtilisin-kexin isoenzyme-1 (SKI-1) activity and reduces glucose-regulated
protein 78 (GRP78) expression in melanoma cells. Dose kinetics of dec-RRLL-
cmk-mediated suppression of SKI-1 activity in SK-Mel-30 cells (a). SKI-1
activity was measured in normalized cell lysates. Depicted is one out of n¼ 3
experiments with similar results. Time kinetics of dec-RRLL-cmk-mediated
suppression of SKI-1 activity in SK-Mel-30 cells (b). Cells were treated with
50mM dec-RRLL-cmk. Normalized cell lysates were assayed for SKI-1 activity.
n¼ 3; **Po0.01 vs. control. Suppression of GRP78 expression by dec-RRLL-
cmk as shown by real-time reverse transcriptase-PCR (RT-PCR; c) and western
immunoblotting (d). Cells were treated with 2mg ml 1 tunicamycin (Tm) for
6 hours (RT-PCR) or 12 hours (western immunoblotting). Dec-RRLL-cmk was
preincubated for 1 hour. Panels c and d are representative sets of three
independent experiments. Contr., control.
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Figure 4. Decanoyl-RRLL-chloromethylketone (Dec-RRLL-cmk) reduces
melanoma cell growth in vitro and in vivo. Metabolic activity was measured
by 2,3-Bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilid-
salt test where metabolic activity of vehicle-treated cells was set at 100% (a).
n¼ 3; *Po0.05, **Po0.01, ***Po0.001, ****Po0.0001. Cell proliferation
was measured by crystal violet assay (b). Proliferation of vehicle-treated cells
was set at 100%. n¼ 3; *Po0.05, **Po0.01, ***Po0.001, ****Po0.0001.
Dec-RRLL-cmk reduces melanoma growth in immunodeficient NSG
(NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice (c). Dec-RRLL-cmk (100mM) versus
phosphate-buffered saline (PBS)/vehicle control was injected three times
per week into established tumors (30 mm3) induced by intracutaneously
injected WM9 melanoma cells. n¼ 7 mice per treatment group.
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inhibitor. To test whether dec-RRLL-cmk can also suppress
melanoma cell growth in vivo, we injected WM9 mela-
noma cells intracutaneously into immunodeficient NSG
(NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice. Once tumors had
a defined size of 30 mm3, they were injected with the SKI inhi-
bitor (100mM) or phosphate-buffered saline vehicle as control.
In accordance with our in vitro data, dec-RRLL-cmk signifi-
cantly suppressed melanoma growth in this model (Figure 4c).
SKI-1 inhibition induces apoptosis of melanoma cells by
a non-ATF6-dependent mechanism
We hypothesized that dec-RRLL-cmk leads to apoptosis of
melanoma cells. Giemsa staining of SK-Mel-30 melanoma
cells treated with 30 and 50mM dec-RRLL-cmk for 48 hours
indeed disclosed morphological changes reminiscent of
apoptosis, e.g., cell shrinkage and nuclear condensation
(Figure 5a). Cell death detection ELISA (CDDE) revealed that
exposure of melanoma cells to 30–75mM dec-RRLL-cmk
results in a dose-dependent formation of mono- and
oligonucleosomes (Figure 5b). This effect was caspase-3-
mediated, as processing of poly-adenosine diphosphate-ribose
polymerase 1/2 could be detected in cells treated with 50mM
dec-RRLL-cmk for 3 hours (Figure 5b insert). Reprobing of the
membrane with an anti-a-tubulin Ab revealed identical
amounts of protein in the lanes (data not shown). The
apoptosis-inducing effect of dec-RRLL-cmk on melanoma cells
was finally confirmed by Annexin-V staining. Dec-RRLL-cmk
(50mM) increased surface expression of phosphatidyl serine
comparable to cells treated with staurosporine (Figure 5c).
To clarify the molecular mechanism as to how SKI-1
inhibition by dec-RRLL-cmk leads to apoptosis, we hypo-
thesized that ATF6 is a critical substrate. ATF6 is processed to
ATF6a-p50 by SKI-1 (Haze et al., 1999; Pullikotil et al., 2007).
Functionally active ATF6a-p50 translocates to the nucleus
and binds to ATF6 consensus sequences. Notably, ATF6
was recently reported to exert an essential role in survival of
insulinoma cells in the absence of endoplasmic reticulum
stress (Teodoro et al., 2012). Therefore, we first examined
the impact of dec-RRLL-cmk on ATF6 expression and sub-
cellular localization. In fact, treatment of SK-Mel-30 cells
with dec-RRLL-cmk reduced the total protein amounts of
processed ATF6, as shown by western immunoblotting using
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Figure 5. Decanoyl-RRLL-chloromethylketone (Dec-RRLL-cmk) induces apoptosis of melanoma cells independent of ATF6. Morphology of SK-Mel-30 cells after
dec-RRLL-cmk treatment (a). Dec-RRLL-cmk-mediated apoptosis of SK-Mel-30 cells as shown by cell death detection ELISA (CDDE; b) and poly-adenosine
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apoptosis of SK-Mel-30 cells as shown by Annexin-V staining (c). Reduced protein levels and nuclear exclusion of ATF6a-p50 as shown by western
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an ATF6a-p50-specific Ab (Figure 5d). This was paralleled by
nuclear exclusion of ATF6a-p50 in cells treated with dec-
RRLL-cmk, as highlighted by double immunofluorescent
staining (Figure 5e). To test whether depletion of ATF6 is
sufficient to induce apoptosis, we performed gene silencing of
ATF6 using small interfering RNA (siRNA). As transfection of
SK-Mel-30 with ATF6 siRNA did not reduce ATF6 mRNA
levels (data not shown), we used WM9 cells. Here, 48-hour
treatment with a pool of ATF6 siRNA oligonucleotides led to
reproducible suppression of ATF6 mRNA expression by
490%. However, ATF6 gene silencing did not lead to
apoptosis in these cells, as shown by CDDE (Figure 5f and g).
Other apoptosis read-outs including caspase 3 activity assays
also failed to demonstrate induction of apoptosis of WM9
melanoma cells upon ATF6 gene silencing (data not shown).
Similar results were obtained with alternative siRNA ATF6
constructs and with other melanoma cell lines (data not
shown). In summary, these findings strongly suggest that
apoptosis of melanoma cells induced by dec-RRLL-cmk is
independent of ATF6.
DISCUSSION
In this report, we have shown that human pigment cells express
SKI-1, a member of the PC family. Although melanocytes are
derived from neuroectoderm, our knowledge on PCs in pigment
cells is still limited. Previously, PC1/3, PC2, paired basic amino
acid cleaving enzyme 4, and furin were detected in NHMs
(Peters et al., 2000; Spencer et al., 2008). It was suggested that
they process proopiomelanocortin into a-MSH, the latter acting
in an autocrine manner in melanocytes and/or in a paracrine
manner on epidermal keratinocytes (Slominski, 1991; Moore
et al., 1999; Schallreuter et al., 1999). However, the latter PCs
are also implicated in the generation of other neurohormones
such as b-endorphin or enkephalin (Slominski et al., 2000;
Slominski et al., 2011), whereas SKI-1 by means of regulating
cholesterol biosynthesis may participate in steroidogenesis
within the skin (Slominski et al., 2008).
Our expression analysis of SKI-1 in NHMs and melanoma
cells in vitro did not reveal differences in SKI-1 expression at
first. However, SKI-1 activity was significantly higher in
conditioned media of the majority of tested melanoma cell
lines than in NHMs. The latter suggest that SKI-1 released by
melanoma cells may confer growth advantage presumably by
processing and activating a secreted paracrine growth factor or
another substance. However, preliminary data with dec-RRLL-
cmk-treated WM9 cells indicated that conditioned medium
does not abrogate the growth-suppressing effect of the SKI-1
inhibitor in vitro.
Notably, in normal human skin SKI-1, expression was
localized primarily in suprabasal epidermal keratinocytes,
whereas basal keratinocytes and melanocytes were non-
reactive. These findings suggest a role of SKI-1 for keratino-
cyte differentiation. In accordance with our SKI-1 activity
assays in melanoma cells in vitro, we found SKI-1 mRNA
and enzyme activity levels to be significantly elevated in
metastatic melanomas compared with normal skin. Further,
SKI-1 immunoreactivity was detected in tumor cells of
melanoma metastases. Future studies on a larger panel of
melanoma specimens are needed to clarify whether SKI-1
expression is related to tumor progression or metastasis.
Our functional studies on SKI-1 in human pigment cells
disclosed an essential role for this PC in cell survival. The
crucial function of SKI-1 for melanoma cell growth was
demonstrated by pharmacological studies using the cell-
permeable and highly specific enzyme inhibitor dec-RRLL-
cmk in melanoma cells in vitro, as well as in vivo in
immunodeficient mice. It was previously shown that dec-
RRLL-cmk at doses of p100mM specifically inhibits SKI-1
(Pasquato et al., 2006). The prosurvival role of SKI-1 in
pigment cells, as highlighted in our study, is supported by
others. Cartilage-specific SKI-1 knockout mice displayed an
increase in chondrocyte apoptosis in the cartilage (Patra et al.,
2007). Future in vivo studies will have to further assess the
potency of dec-RRLL-cmk on tumor growth and metastasis in
melanoma animal models.
With regard to the molecular mechanism of apoptosis
mediated by dec-RRLL-cmk, we demonstrated that several
SKI-1 substrates/target genes are affected. Co-treatment of
SK-Mel-30 cells with the SKI-1 inhibitor plus tunicamycin
reduced GRP78 expression compared with tunicamycin
alone. Although little is known on the function of ATF6 in
melanoma, it was recently shown that siRNA of GRP78
induces apoptosis of melanoma cells (Martin et al., 2010).
However, gene silencing of ATF6 by siRNA failed to induce
apoptosis in our hands despite the fact that dec-RRLL-cmk
markedly reduced the protein levels of ATF6a-p50. These
findings suggest that ATF6—in contrast to insulinoma cells
(Teodoro et al., 2012)—does not regulate basal GRP78
expression in melanoma cells. In support of this, basal
GRP78 mRNA levels were not altered by treatment of
melanoma cells with dec-RRLL-cmk (data not shown).
Future studies are thus needed to identify critical target
genes or substrates that mediate apoptosis of melanoma cells
following SKI-1 inhibition.
MATERIALS AND METHODS
Cells, chemicals, and stimulation
All melanoma cell lines were maintained as described (Li et al.,
2004). WM35, WM902B, and WM9 cells were a gift from M. Herlyn
(The Wistar Institute, Philadelphia, PA), A375 and G361 were from
ATCC (Rockville, ML), and IPC298, IGR37, and SK-Mel-30 cells were
from DSMZ (Braunschweig, Germany). NHMs were purchased from
Tebu-bio (Portland, OR) and cultured as described (Kokot et al.,
2009). Before stimulation with growth factors, NHMs were deprived
for 48 hours from TPA or bovine pituitary extract. Dec-RRLL-cmk was
from Bachem (Weil am Rhein, Germany), tunicamycin and TPA from
Sigma (St Louis, MO), forskolin and a-MSH from Calbiochem
(Schwalbach, Germany), basic fibroblast growth factor and tumor
necrosis factor-a from Immunotools (Friesoythe, Germany), and IL-1b
from Biomol (Hamburg, Germany). UVB irradiation of NHMs was
performed as described (Kokot et al., 2009).
RNA extraction, real-time RT-PCR, and sequencing
Standard protocols were used for total RNA preparation from cells
and tissue sections, for semiquantitative and real-time RT-PCRs and
for DNA sequencing. They are described in the Supplementary
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Information online. Expression analysis of SKI-1 in human skin and
melanoma samples derived from routine diagnostic and thera-
peutic procedures was approved by the Local Ethical Committee of
the University of Mu¨nster. Established primer sets were used for
glyceraldehyde-3-phosphate dehydrogenase (Kokot et al., 2009), 18S
rRNA (Natarajan et al., 2010), SKI-1 (Dubuc et al., (2004), GRP78
(Yan et al., 2010), and ATF6 (Namba et al., 2007).
ATF6 gene silencing
A pool of four siRNA oligonucleotides (SMARTpool; Thermo
Scientific Dharmacon, Bonn, Germany) was used to deplete cells
from ATF6. Nontargeting control siRNA was used as negative control.
Cells were transfected for 48 hours with siRNA at a final concen-
tration of 25 nM according to the manufacturer’s instructions.
Western immunoblotting
Routine protocols were used for preparation of cell lysates,
SDS-PAGE, western blotting, and immunoprobing (Kokot et al.,
2009). For detection of SKI-1 protein in conditioned media, NHMs
and melanoma cells were first cultured for 48 hours in TPA-free
medium (DermaLife M Basal medium (CellSystems, St Katharinen,
Germany)), followed by harvesting of the supernatants, centrifugation,
and concentration by Amicon-Ultra Centrifugal Filters 30 K
(Millipore, MA). Fractions of B250ml were collected and norma-
lized for protein content. The primary Abs were anti-SKI-1 (Santa Cruz
Biotechnology, Heidelberg, Germany, H-300, 1mg ml 1), anti-poly-
adenosine diphosphate-ribose polymerase 1/2 (Santa Cruz Bio-
technology, H-250, 1:200), anti-GRP78 (Cell Signaling Technology,
Danvers, MA, 1:1,000), and anti-ATF6a-p50 (Teodoro et al., 2012;
1:1,000). Equal protein loading was assured by reprobing with an
anti-a-tubulin Ab (Oncogene Research Products, San Diego, CA,
1:1,000) or anti-b-actin Ab (Santa Cruz Biotechnology, 1:1,000).
Immunofluorescence analysis in vitro
For detection of SKI-1 and ATF6a-p50 by immunofluorescence,
10,000 cells per well were seeded into eight-well chamber slides
(Nalge Nunc International, Naperville, IL). Immunostaining proce-
dures are further described in the Supplementary Information. The
Abs were anti-NKI/beteb (Caltag Medsystems, Buckinghamshire, UK,
1:30), anti-SKI-1 (kindly provided by Dr NG Seidah, Clinical Research
Institute of Montreal, Canada; 1:100), and anti-ATF6a-p50 (Teodoro
et al., 2012; 1:100).
Immunofluorescence analysis in situ
Cryostat sections were mounted on Superfrost Plus slides (Thermo
Scientific, Braunschweig, Germany), air-dried, and fixed in ice-cold
acetone for 10 minutes. After washing with 0.1 M TBS-T (DCS
Diagnostics, Hamburg, Germany), slides were blocked with 2%
BSA diluted in 0.1 M TBS-T for 30 minutes, and incubated for 4 hours
with the anti-SKI-1 Ab (Santa Cruz Biotechnology, H-300, 1mg ml 1)
and the anti-NKI/beteb Ab (GeneTex, Irvine, CA, 1:10). After washing,
slides were incubated for 1 hour with secondary Abs coupled to FITC
(Dako, Hamburg, Germany, 1:50) and Texas red (Dianova, Hamburg,
Germany, 1:400), followed by washing and mounting in Vectashield
(Vector Laboratories, Burlingame, CA). The sections were viewed
with a fluorescence microscope (Carl Zeiss, Oberkochen, Germany).
As negative control, rabbit IgG was used at the same concentration as
the primary Ab.
In silico promoter analysis
Comparative promoter analysis of SKI-1 was performed with the
Java program TOUCAN (Aerts et al., 2005). Further details are
provided in the Supplementary Information online.
SKI-1 activity assay
Enzyme assays were performed with Ac-RSLK-AMC (Bachem), which
is cleaved by SKI-1 into Ac-RSLK and 7-amino-4-methylcoumarin
(AMC). AMC is a fluorescent compound that can be subsequently
measured to determine SKI-1 activity. To measure SKI-1 activity,
in vitro cell lysates were prepared as described (Kokot et al., 2009),
whereas conditioned media were processed as described above.
To measure SKI-1 activity, ex vivo fresh tissue was placed into lysis
buffer and homogenized by TissueLyserII (Qiagen, Santa Clarita, CA).
All samples were normalized for protein content. Identical protein
amounts per sample (cell lysates: 8–25mg; conditioned media: 20mg;
tissue lysates: 25mg) were then incubated with prewarmed substrate
in the dark for 15 minutes at 37 1C in assay buffer consisting of 25 mM
Tris, 25 mM 2-(N-morpholino)ethanesulfonic acid, and 1 mM CaCl2
(pH 7.5). Ac-RSLK-AMC was added to the reaction mixture (total
volume 100ml; final concentration 100mM). The reaction was stopped
at indicated time points with 100ml of ice-cold 5 mM EDTA. AMC
generation was measured with a spectrofluorometer (Infinite M200,
Tecan, Ma¨nnedorf, Switzerland; excitation: 360 nm; emission:
460 nm) against a standard curve generated with AMC (Molekula,
Munich, Germany). All samples were assayed in duplicate.
Giemsa staining
Giemsa staining of SK-Mel-30 cells exposed to dec-RRLL-cmk in the
presence of 1% fetal calf serum was performed as described before
(Ramser et al., 2009).
In vitro growth assays
Metabolic activity and cell proliferation were measured by routine
protocols, as outlined in the Supplementary Information online.
Apoptosis assays
Apoptosis was measured by CDDE and Annexin-V FACS analysis as
described before (Bo¨hm et al., 2005). All apoptosis read-outs were
performed on cells cultured in the presence of 1% fetal calf serum.
In vivo efficacy studies
Animal studies were conducted in immunodeficient NSG (NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ) mice (purchased from Dr Leonard Schultz,
The Jackson Laboratory) under institutional approval (animal proto-
col 8.87–50.10.36.08.286). Mice were used at an age of 8–14
weeks. WM9 melanoma cells (1 105 cells per animal) were
injected intracutaneously into 14 NSG mice. Tumor size was
measured every other day using a caliper. Once tumors had reached
a size of 30 mm3, they were injected three times a week with 20ml of
dec-RRLL-cmk (100mM; n¼ 7) or phosphate-buffered saline/vehicle
(n¼ 7). Mice were killed when tumors had reached a final size of
1 cm3 or became ulcerated.
Statistical analysis
All experiments were performed at least three times. Statistical
significance of the means±SD or SEM was determined by the
Student’s t-test using Origin 6.0 G (OriginLab, Northampton, MA) or
IBM SPSS 20.0 (Dynelytics, Zu¨rich, Switzerland).
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